Lv7
3910 积分 2021-10-14 加入
胃癌Claudin18.2临床检测专家共识（2025版）
2天前
已完结
Glioblastoma: a comprehensive approach combining bibliometric analysis, Latent Dirichlet Allocation, and HJ-Biplot
3天前
已完结
Evolution of claudin18.2 therapies in gastroesophageal cancers
17天前
已完结
Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer
23天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
30天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
30天前
已完结
Differentiating IL-23 Inhibitors in Crohn’s Disease
30天前
已完结
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
1个月前
已完结
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
1个月前
已完结
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
1个月前
已完结
皖公网安备34019202002308
